Nobelpreis für Medizin und Physiologie 2023 für Grundlagenforschung auf dem Gebiet der mRNA

• Literatur

• 1 Vaccines and immunization. (o. J.). Abgerufen 8. Oktober 2023, von. https://www.who.int/health-topics/vaccines-and-immunization
• 2 Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: Article 7161
• 3 Plotkin SA. Vaccines: The fourth century. Clinical and Vaccine 16 (12) 1709-1719
• 4 Pardi N, Hogan MJ, Porter FW. et al. mRNA vaccines – A new era in vaccinology. Nature Reviews Drug Discovery 2018; 17 (04) Article 4
• 5 Weissman D, Ni H, Scales D. et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. Journal of Immunology (Baltimore, Md.: 1950) 2000; 165 (08) 4710-4717
• 6 Karikó K, Bhuyan P, Capodici J. et al. Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells, Tissues, Organs 2004; 177 (03) 132-138
• 7 Ni H, Capodici J, Cannon G. et al. Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-alpha secretion and signaling through a nucleotide receptor. The Journal of Biological Chemistry 2002; 277 (15) 12689-12696
• 8 Koski GK, Karikó K, Xu S. et al. Cutting edge: Innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. Journal of Immunology (Baltimore, Md.: 1950) 2004; 172 (07) 3989-3993
• 9 Karikó K, Buckstein M, Ni H. et al. Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23 (02) 165-175
• 10 Anderson BR, Muramatsu H, Nallagatla SR. et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Research 2010; 38 (17) 5884-5892
• 11 Karikó K, Muramatsu H, Welsh FA. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy: The Journal of the American Society of Gene Therapy 2008; 16 (11) 1833-1840
• 12 Karikó K, Muramatsu H, Keller JM. et al. Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin. Molecular Therapy 2012; 20 (05) 948-953
• 13 Pardi N, Hogan MJ, Pelc RS. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 2017; 543: Article 7644
• 14 Polack FP, Thomas SJ, Kitchin N. et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. New England Journal of Medicine 2020; 383 (27) 2603-2615
• 15 Sahin U, Muik A, Derhovanessian E. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020; 586: Article 7830
• 16 Oberhardt V, Luxenburger H, Kemming J. et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature 2021; 597: 268-273
• 17 Boczkowski D, Nair SK, Snyder D. et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. Journal of Experimental Medicine 1996; 184 (02) 465-472
• 18 Sahin U, Derhovanessian E, Miller M. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547: 222-226
• 19 Rojas LA, Sethna Z, Soares KC. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023; 618: Article 7963
• 20 Kon E, Ad-El N, Hazan-Halevy I. et al. Targeting cancer with mRNA–lipid nanoparticles: Key considerations and future prospects. Nature Reviews Clinical Oncology 2023; 1-16
• 21 Zong Y, Lin Y, Wei T. et al. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy. Advanced Materials (Deerfield Beach, Fla.) 2023; e2303261